Chai Discovery has entered into a licensing agreement with Pfizer to support the use of artificial intelligence in drug discovery and accelerate the development of new medicines.

Alnylam Pharmaceuticals, Inc. and Inceptive Nucleics, Inc. have entered into a strategic collaboration aimed at accelerating the discovery and development of RNA interference (RNAi) therapeutics through the use of artificial intelligence.

First Foundation Labs (1FL), a life sciences artificial intelligence company established by Luma Group, has announced a collaboration with Microsoft to support the development and enterprise deployment of its

Vertex Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for povetacicept, an investigational treatment for adults with immunoglobulin A nephropathy (IgAN).

Pfizer and Innovent Biologics have entered into a global strategic licensing and collaboration agreement to support the research and development of 12 early-stage cancer medicines. The partnership covers antibody-drug conjugates

Nanoscope Therapeutics has selected McKesson’s InspiroGene platform to support the US commercialisation of its lead retinal therapy candidate, MOGENRY™, subject to regulatory approval in the country.

Insilico Medicine and Human Longevity have announced a multi-million-dollar collaboration to co-develop what the companies describe as the industry’s first large-scale artificial intelligence (AI) foundation model focused on human longevity science.

Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy Claude Enterprise across its global operations.

MEKanistic Therapeutics has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug (IND) application for MTX-531, allowing the company to begin a Phase 1 clinical trial in advanced solid tumours.

Bio-Thera Solutions and Accord BioPharma have announced that the US Food and Drug Administration (FDA) has approved IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), the first biosimilars to Simponi® and Simponi Aria® in the United States.